Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myozenin-3 (MYOZ3) is a muscle-specific, Z-disc–associated intracellular protein expressed predominantly in fast-twitch skeletal muscle, and to a lesser extent in cardiac muscle[1][2][3]. It functions primarily as a structural and signaling adapter, interacting with calcineurin, α-actinin, γ-filamin, telethonin, and LDB3/ZASP at the sarcomere[2][3]. MYOZ3 modulates calcineurin signaling, which is important for determining muscle fiber type and muscle cell growth[1][3]. Unlike typical molecular therapeutic targets like receptors or enzymes, MYOZ3 is not currently considered a classic therapeutic target for drugs, though it has been investigated as a candidate gene in neuromuscular and congenital contracture syndromes[2][3]. There are no established small-molecule or biological drugs that target MYOZ3, and no known safety or biomarker data regarding its modulation in disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myozenin-3 (MYOZ3).